European Biosimilars Revenues Pull Celltrion Through In Q3
As Prolia And Xgeva Rivals Become First Approved Biosimilars In South Korea
Celltrion’s focus on European expansion has paid off but is overshadowed by “lackluster” Zymfentra revenues in the US.
